Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This is a combination of creatine monohydrate, a dietary supplement and naturally occurring compound involved in cellular energy metabolism, and escitalopram, a selective serotonin reuptake inhibitor (SSRI) antidepressant. Creatine supplementation increases brain phosphocreatine stores, supporting ATP regeneration and neuroenergetic processes. Escitalopram inhibits the reuptake of serotonin (5-HT) into presynaptic neurons, increasing synaptic serotonin levels to alleviate depressive symptoms. Clinical studies have shown that adding creatine to escitalopram therapy in patients with major depressive disorder can accelerate the onset of antidepressant effects and enhance overall treatment efficacy compared to SSRI alone[3][4][5][7]. The combination is being investigated primarily for its potential benefits in mood disorders such as depression.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on creatine monohydrate + escitalopram.